UFP Industries Expands PalletOne's northeast Footprint Through Acquisition of John Rock, Inc.
Get Alerts UFPI Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.4%
Revenue Growth %: -2.7%
Join SI Premium – FREE
John Rock, a subsidiary of Kamps Pallets, designs and manufactures new pallets across
This acquisition strengthens a core business for UFP Industries and expands PalletOne's scale in a strategically important geography. The transaction includes all key operating assets of John Rock, allowing for immediate manufacturing and service continuity while providing a strong platform for operational improvement and long‑term growth.
"This acquisition is fundamentally about strengthening our core packaging business and expanding our footprint in a region where we see long‑term opportunity," said
The acquired operations will be integrated into PalletOne's existing manufacturing network, creating opportunities to improve efficiency, enhance service levels, leverage UFP's procurement and operational capabilities, and growth with national customers — while maintaining the local expertise and customer focus that has defined John Rock's success.
"John Rock is a well‑known name in the northeast pallet market, with a strong team and a diverse customer base," said
The acquisition underscores UFP Industries' continued focus on investing in its core businesses, expanding manufacturing capacity in key markets, enhancing its ability to serve national customers, and strengthening the competitive position of its operating companies across packaging and industrial markets.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ufp-industries-expands-palletones-northeast-footprint-through-acquisition-of-john-rock-inc-302761483.html
SOURCE UFP Industries, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UK Charity Helping Ukrainian Children Build Global Futures Welcomes First External Advisor
- Introduces POS Ready for FWA12 to Help Retailers and Restaurants Protect Payment Traffic
- Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share